The number of antibiotic-resistant strains continues to rise rapidly. Statistics from the Centers for Disease Control and Prevention (CDC) and the Infectious Diseases Society of America (IDSA) point to alarming trends that are...
It is with great excitement that we unveil our network-wide redesign. Please read further to learn more about a few of our new features, and browse around to explore the new site!
Patients with heart failure and reduced ejection fraction (HF-REF) treated with an investigational angiotensin receptor neprilysin Inhibitor (ARNI) are more likely to reduce cardiovascular death and heart failure hospitalization than...
Teens who received the collaborative care intervention in primary care had significantly greater improvements in depressive symptoms than teens who were receiving treatment as usual.

FDA APPROVALS
FDA grants Lucentis breakthrough ...

The FDA has granted breakthrough therapy designation for Lucentis (ranibizumab, Genentech) for the treatment of diabetic ...

FDA approves first therapy for ...
FDA grants first-ever CLIA waiver of ...
New screening test predicts risk of ...

CLINICAL
FDA approves first therapy for ...

FDA has approved lanreotide (Somatuline Depot, Ipsen) Injection, 120 mg (referred to as Somatuline) for the treatment of ...

FDA grants Lucentis breakthrough ...
Novel new drugs approved in 2014
FDA grants first-ever CLIA waiver of ...

DRUGS IN PERSPECTIVE
Drugs in Perspective: Myalept ...

Myalept (metreleptin) is a leptin analogue with the same physiologic effects as leptin.11 Metreleptin was granted a ...

Drugs in Perspective: Otezla ...
Drugs in Perspective: Zykadia ...
Drugs in Perspective: Dalvance

Latest Tweets Follow